Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard T Mahoney

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
Health Research Policy and Systems|August 30, 2011
Product Development Partnerships: Case studies of a new mechanism for health technology innovationRichard T Mahoney
Human Vaccines|July 13, 2011
Getting priorities straightRichard T Mahoney
Bulletin of the World Health Organization|May 20, 2006
Intellectual property and public healthAnatole Krattiger, Richard T Mahoney
Human Vaccines|July 8, 2011
Estimating potential demand and supply of dengue vaccine in BrazilAnanda Amarasinghe, Richard T Mahoney
Vaccine|January 27, 2004
The introduction of new vaccines into developing countries. III. The role of intellectual propertyRichard T Mahoney, Ariel Pablos-Mendez, S Ramachandran
Plos One|March 4, 2014
Monitoring what governments "give for" and "spend on" vaccine procurement: Vaccine Procurement Assistance and Vaccine Procurement BaselineE A S Nelson, David E Bloom, Richard T Mahoney
Vaccine|March 23, 2005
Policymakers' views regarding the introduction of new-generation vaccines against typhoid fever, shigellosis and cholera in AsiaDenise DeRoeck, John D Clemens, Andrew Nyamete, et al.
Human Vaccines|October 9, 2010
Forecasting dengue vaccine demand in disease endemic and non-endemic countriesAnanda Amarasinghe, Ole Wichmann, Harold S Margolis, et al.
Vaccine|March 17, 2007
The introduction of new vaccines into developing countries. IV: Global Access StrategiesRichard T Mahoney, Anatole Krattiger, John D Clemens, et al.
Plos Neglected Tropical Diseases|March 22, 2013
Will dengue vaccines be used in the public sector and if so, how? Findings from an 8-country survey of policymakers and opinion leadersDon L Douglas, Denise A DeRoeck, Richard T Mahoney, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Health Research Policy and Systems|August 30, 2011
Product Development Partnerships: Case studies of a new mechanism for health technology innovationRichard T Mahoney
Human Vaccines|July 13, 2011
Getting priorities straightRichard T Mahoney
Bulletin of the World Health Organization|May 20, 2006
Intellectual property and public healthAnatole Krattiger, Richard T Mahoney
Human Vaccines|July 8, 2011
Estimating potential demand and supply of dengue vaccine in BrazilAnanda Amarasinghe, Richard T Mahoney
Vaccine|January 27, 2004
The introduction of new vaccines into developing countries. III. The role of intellectual propertyRichard T Mahoney, Ariel Pablos-Mendez, S Ramachandran
Plos One|March 4, 2014
Monitoring what governments "give for" and "spend on" vaccine procurement: Vaccine Procurement Assistance and Vaccine Procurement BaselineE A S Nelson, David E Bloom, Richard T Mahoney
Vaccine|March 23, 2005
Policymakers' views regarding the introduction of new-generation vaccines against typhoid fever, shigellosis and cholera in AsiaDenise DeRoeck, John D Clemens, Andrew Nyamete, et al.
Human Vaccines|October 9, 2010
Forecasting dengue vaccine demand in disease endemic and non-endemic countriesAnanda Amarasinghe, Ole Wichmann, Harold S Margolis, et al.
Vaccine|March 17, 2007
The introduction of new vaccines into developing countries. IV: Global Access StrategiesRichard T Mahoney, Anatole Krattiger, John D Clemens, et al.
Plos Neglected Tropical Diseases|March 22, 2013
Will dengue vaccines be used in the public sector and if so, how? Findings from an 8-country survey of policymakers and opinion leadersDon L Douglas, Denise A DeRoeck, Richard T Mahoney, et al.
Pageof 2